Merus N.V. Reports Q3 2025 Revenue Growth to $12.15 Million Amid Continued Operating Losses

Merus N.V. reported its financial results for the third quarter of 2025, revealing a total revenue of $12.15 million, a slight increase from $11.77 million in the same period last year. The revenue growth was primarily driven by collaboration revenue, which rose to $11.87 million from $11.77 million, and included a notable contribution of $5.6 million from Gilead, marking a significant increase compared to the previous year. However, the company continues to face substantial operating losses, reporting a net loss of $95.52 million for the quarter, slightly less than the $99.91 million loss recorded in Q3 2024.

In terms of operational expenses, Merus experienced a significant rise, with total operating expenses reaching $108.63 million, up from $84.00 million in the prior year. This increase was largely attributed to higher research and development costs, which surged to $80.02 million from $63.24 million, reflecting intensified clinical trial activities, particularly for its lead candidate, petosemtamab. General and administrative expenses also increased, totaling $28.61 million compared to $20.77 million in the same quarter last year.

Merus's financial position showed improvement, with cash and cash equivalents increasing to $367.49 million as of September 30, 2025, up from $293.29 million at the end of 2024. The company also reported marketable securities of $268.44 million, contributing to total current assets of $691.93 million, compared to $569.07 million at the end of the previous fiscal year. This increase in liquidity is crucial as the company anticipates continued significant expenses related to its clinical trials and product development.

Strategically, Merus entered into a transaction agreement with Genmab A/S on September 29, 2025, which involves a cash tender offer for all outstanding common shares at $97.00 per share. This agreement is subject to various conditions and could result in Merus becoming an indirect wholly-owned subsidiary of Genmab. The company is also actively pursuing collaborations and licensing agreements to enhance its product pipeline and financial stability, including a recent collaboration with Biohaven to co-develop bispecific antibody drug conjugates.

Looking ahead, Merus expects to continue incurring significant operating losses as it advances its clinical programs, particularly for petosemtamab and zenocutuzumab, which have shown promise in treating various cancers. The company projects that its existing cash and marketable securities will fund operations into 2028, although it acknowledges the potential need for additional financing if the Genmab transaction does not close as planned. The ongoing geopolitical and economic uncertainties may also impact its ability to raise capital in the future.